Results 111 to 120 of about 50,964 (281)

Management of Advanced Prostate Cancer in the Asia‐Pacific Region: Summary of the Asia‐Pacific Advanced Prostate Cancer Symposium 2025

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Summary of the Asia Pacific Advanced Prostate Cancer Symposium 2025, showing disciplines and diversity of participants, discussion topics (high‐risk localized/locally advanced prostate cancer; PSA persistence and recurrence; radioligand therapy; genetics and genomics; bone protection and other aspects of supportive care), key themes, and high‐level ...
Edmund Chiong, Renu Eapen, Nicholas Buchan, Kenneth Chen, Lukman Hakim, Agus Rizal Hamid, Jae‐Young Joung, Ravindran Kanesvaran, Makarand Khochikar, Jason Letran, Bannakij Lojanapiwat, Indranil Mallick, Chi Fai Ng, Pei Ing Ngam, Teng Aik Ong, Jacob Pang, Darren M. C. Poon, Natasha Roberts, Marniza Saad, Shinichi Sakamoto, Jeremy Tey, Sue Ping Thang, Poh Choo Toh, Levent Türkeri, Nguyễn Tuấn Vinh, Alvin Wong, Yao Zhu, ANZUP Cancer Trials Group, Ian D. Davis   +28 more
wiley   +1 more source

Castration Resistant Prostate Cancer: Role of Chemotherapy

, 2016
The last decade brought many new treatment options that changed the treatment algorithms for metastatic castrate-resistant prostate cancer (mCRPC). One of the most challenging tasks today is the optimal sequencing of agents since timing and patient ...
Marijo Bilusic, Bilusic, Marijo
core   +1 more source

Active surveillance for intermediate risk prostate cancer: the Manitoba Prostate Center experience

BJU International, EarlyView.
Objectives To report long‐term oncological outcomes of men with intermediate‐risk prostate cancer managed with active surveillance at a single centre. Subjects/Patients and Methods We retrospectively analysed a prospectively maintained Manitoba Prostate Centre active surveillance database.
Steven Lu, Connor Roque, Jeff Saranchuk, Ardalan E. Ahmad   +3 more
wiley   +1 more source

FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer

, 2012
Forkhead box protein A1 (FOXA1) modulates the transactivation of steroid hormone receptors and thus may influence tumor growth and hormone responsiveness in prostate cancer.
Fabian Huber, Beer, Marc, Wild, P J, Josefine Gerhardt, Matteo Montani, Hermanns, Thomas, Glen Kristiansen, Kristiansen, G, Müntener, Michael, Marc Beer, Hermanns, T, Montani, Matteo, Kristiansen, Glen, Beer, M, Michael Müntener, Gerhardt, Josefine, Gerhardt, J, Huber, Fabian, Thomas Hermanns, Peter Wild, Huber, F, Müntener, M, Montani, M, Wild, Peter   +23 more
core   +1 more source

About sorafenib in castration-resistant prostate cancer

Annals of Oncology, 2008
n ...
Colloca, G., Checcaglini, F., Venturino, A.   +2 more
openaire   +3 more sources

Mapping the Radiopharmaceutical Therapy Landscape for Prostate Cancer: Insights Into Global Clinical Trial Trends and Future Directions

Med Research, EarlyView.
Zhiwu Dong, Sixiang Yan, Xiaodong Liu, Peng Gu   +3 more
wiley   +1 more source

Intermediate clinical endpoints as surrogates for overall survival after salvage prostatectomy

BJU International, EarlyView.
Objectives To evaluate biochemical recurrence‐free survival (BRFS) and metastasis‐free survival (MFS) as potential intermediate clinical endpoints (ICEs) for overall survival (OS) in patients undergoing salvage radical prostatectomy (sRP). Patients and Methods Evaluable patients were selected from a retrospective dataset, resulting in a cohort of 879 ...
Navid Roessler, Zuzanna Nowicka, Marcin Miszczyk, Giorgio Calleris, Alessandro Dematteis, Malte W. Vetterlein, Simone Albisinni, Henk G Van Der Poel, Paul Cathcart, Giovanni E. Cacciamani, Inderbir S. Gill, Raj A. Persad, Steven Joniau, Rafael Sanchez‐Salas, Joseph A. Smith Jr, Robert Jeffrey Karnes, Mohamed E. Ahmed, Pawel Rajwa, Derya Tilki, Shahrokh F. Shariat, Paolo Gontero, Giancarlo Marra, on behalf of the Young Academic Urologists Prostate Cancer Working Party   +22 more
wiley   +1 more source

Development of a transcriptional repressor based approach for the treatment of prostate cancer [PDF]

, 2018
Prostate cancer is currently treated with hormonal therapies, which aim to block the production and/or action of androgens. However, tumours eventually progress to castration-resistant prostate cancer and there is therefore still a great need for new ...
Fioretti, Flavia Marialucia
core   +1 more source

Managing Nonmetastatic Castration-resistant Prostate Cancer

European Urology, 2019
Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) have rising prostate-specific antigen (PSA) and castrate testosterone levels, with no radiological findings of metastatic disease on computed tomography and bone scan. Given recent drug approvals for nmCRPC, with many other therapeutics and imaging modalities being developed ...
Mateo, J, Fizazi, K, Gillessen, S, Heidenreich, A, Perez-Lopez, R, Oyen, WJG, Shore, N, Smith, M, Sweeney, C, Tombal, B, Tomlins, SA, de Bono, JS   +11 more
openaire   +6 more sources

Genetic Predictors of Progression and Skin Rash in Japanese mCSPC Patients Treated With Apalutamide: CUARTET Study

Cancer Science, EarlyView.
In patients with mCSPC treated with apalutamide plus ADT, baseline ctDNA predicted earlier progression to CRPC and worse overall survival. Exploratory genome‐wide analysis identified 12 SNPs associated with apalutamide‐related skin rash. ABSTRACT Despite promising evidence of the efficacy of the androgen deprivation therapy (ADT) plus apalutamide in ...
Masaki Shiota, Taku Naiki, Koji Hatano, Akira Yokomizo, Hiroaki Tsuchiya, Yoko Takahashi, Taku Nakayama, Masaki Yoshida, Hirotsugu Uemura   +8 more
wiley   +1 more source